Regulators focus on the completeness, consistency, and retrievability of audit trail data. They evaluate whether the audit trail:

• Captures who made a change (user attribution)
• Includes date and time stamps (in a validated time zone)
• Preserves original and modified values
• Includes a reason for change, especially for deletions
• Is protected from manipulation or deletion by users
• Is reviewed regularly and documented

Systems under scrutiny include:

• EDC: Clinical case report forms (CRFs)
• eTMF: Document upload/review/version control
• IVRS/IWRS: Randomization and drug assignment logs
• LIMS: Lab data edits and releases

For example, during a 2023 FDA inspection, a CRO received a 483 observation for failing to review audit trails showing unauthorized corrections to lab values after database lock. The issue wasn’t just the correction—it was the failure to detect and document it.

Regulatory Frameworks Governing Audit Trails

Expectations for audit trail compliance are outlined in several key regulatory guidelines:

• 21 CFR Part 11 (FDA): Requires secure, computer-generated audit trails for electronic records
• EU GMP Annex 11: Mandates audit trail review “when critical data is changed”
• ICH E6(R3): Expands the definition of data integrity and the need for traceability in quality systems

These documents emphasize not only the existence of audit trails but their periodic review and correlation with SOPs. Auditors will often request:

• Raw audit log exports (CSV or PDF)
• Sample entries that show modifications, deletions, and access changes
• System validation documentation proving the audit trail function cannot be disabled
• Internal procedures describing audit trail review frequency and documentation

To explore validation templates for audit trail functionality, visit pharmaValidation.in.

Audit Trail Review SOPs and Role Assignments

Regulators expect that sponsors and CROs have a documented SOP governing audit trail review. This SOP should include:

• Defined Frequency: e.g., monthly for EDC, per upload event for eTMF
• Responsible Roles: Typically QA, Data Management, and Clinical Monitoring
• Review Triggers: Examples include database lock, SAE reports, out-of-trend values
• Documentation Standards: Use of review checklists, audit trail review logs, and follow-up deviation/CAPA forms

A sample SOP structure may look like this:

Audit Trail Type	Responsible Function	Review Frequency	Output Document
EDC CRF Edits	Clinical Data Manager	Biweekly	EDC Audit Trail Review Log
eTMF Document Replacements	TMF Lead	Per Upload	TMF Audit Snapshot

For downloadable SOP templates, visit PharmaSOP.in.

Common Regulatory Findings Related to Audit Trails

Regulatory authorities frequently cite audit trail deficiencies in inspection reports. Some common findings include:

• Failure to Review Audit Trails: No documented evidence that logs were reviewed prior to DB lock
• Audit Trail Not Enabled: System functionality turned off or never validated
• Missing Reason for Changes: Critical field edits with no explanation or approval
• Uncontrolled Access Logs: No restrictions on who can delete or overwrite audit trails

In one 2022 EMA inspection, a site was found to have deleted patient visit entries from an eSource system without justification. Although the audit trail existed, it was never reviewed. This resulted in a major data integrity violation.

Best Practices for Ensuring Audit Trail Readiness

To prepare for audit trail review during inspections, sponsors and CROs should:

• Ensure all critical systems have validated, immutable audit trail functionality
• Include audit trail checks in routine monitoring visits and RBM dashboards
• Assign clear ownership of audit trail review responsibilities
• Maintain records of all reviews, findings, and resulting actions
• Train users on audit trail awareness and documentation expectations

Many sponsors also conduct periodic internal audits focused solely on audit trail completeness and review adherence.

For automated audit trail tracking tools and ALCOA+ validation plugins, explore technologies at PharmaRegulatory.in.

Conclusion: Audit Trails Are No Longer Optional

As regulators push for greater transparency and accountability in digital clinical trials, audit trails have become a non-negotiable requirement. But it’s not just about having them—it’s about using them actively, documenting your reviews, and understanding what your data history reveals.

Regulatory inspections will continue to dig deeper into audit trail records. Those who treat audit trail review as a proactive governance practice—not a checkbox task—will be best positioned for clean audits and inspection success.

For additional guidance on aligning with EMA and FDA audit trail expectations, review the latest ICH E6(R3) draft and technical notes on ICH.org.